Sign in Subscribe
06
Jan
4 min read

The Efficiency Gap: Why Your Sample Size Calculation is Leaving 30% on the Table

The pharmaceutical industry is facing a cost disease. Bringing a new drug to market now routinely exceeds $2 billion, with patient recruitment standing as the single largest bottleneck. In response, we usually reach for operational fixes: faster sites, simpler protocols, digital recruitment. But there is a mathematical lever that is

30
Dec
6 min read

The Antidote to Guaranteed Significance

What to do instead of UPSIs

16
Dec
5 min read

Stop the Zombie Trial: The "Kill Switch" for Failed Experiments

The most expensive decision in drug development (or product experimentation) is not starting a trial. It is continuing a zombie trial. Imagine you are at the interim analysis of a Phase II study. You have enrolled 50 of 100 patients. You have spent $10 million. The data is... underwhelming. The